



## **Dyve Biosciences to Highlight the Power and Potential of Transdermal Drug Delivery at PODD 2019**

*Ryan Beal, MD, co-inventor of Dyve's revolutionary platform technology, will explain how the company is re-mapping the topical delivery route.*

**October 3, 2019 – Thousand Oaks, California** – Dyve Biosciences, a biotech drug delivery company developing breakthrough platform technology that broadly enables transdermal drug delivery, announced today that its CEO, Ryan Beal, MD, will present at the Partnerships in Drug Delivery conference (PODD), held October 7-8 in Boston. Beal co-invented Dyve's novel transdermal delivery technology, a revolutionary mechanism for fast, effective, targeted treatments.

"At Dyve, we talk about how our platform technology delivers topical medication into the blood 'with needle-like speed and pill-like efficiency,'" said Beal. "I'm excited to discuss this concept and the technology's many applications with attendees of PODD, the top event to illuminate drug delivery advances and trends."

In his presentation, "Broadly Enabling the Power and Potential of Transdermal Drug Delivery," Beal will explain how Dyve technology moves far beyond the long-held limitations of topical medications to improve treatment options in areas ranging from therapeutics to medical dermatology and aesthetics. Current studies of the company's platform delivery technology include pre-clinical and human pharmacokinetic data across two dozen molecules; a clinical trial of a new standard of care for acute gout pain; and a clinical trial of transdermal melasma therapy that meets or exceeds results from invasive treatment options.

Physicians and industry leaders at PODD are invited to attend:

Broadly Enabling the Power and Potential of Transdermal Drug Delivery

- Ryan Beal, MD, CEO of Dyve Biosciences
- Monday October 7, 5 p.m.
- Renaissance Boston Waterfront Hotel, Boston

### **About Dyve Biosciences**

Dyve Biosciences is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary Dyve skin penetration technology. The innovative approach enables



therapy to be transported from the surface of the skin into the blood with need-like speed and pill like efficiency. Dyve has advanced clinical programs in gout and melasma. At Dyve, the focus is on robust science, compelling data, and delivering positive patient outcomes. For more information please visit [www.dyvebio.com](http://www.dyvebio.com).

**Contact**

Audra B. Friis

audra@pascalecommunications.com

917.519.9577

###